Effect of Zinc Supplement on Improvement of Homostatus Glucose in Thalassemia Major and Intermedia with Zinc Deficiency
Early Phase 1
Completed
- Conditions
- Homostatus Glucose Disorder in Thalassemia Major and Intermedia with Zinc Deficiency.
- Registration Number
- IRCT20190301042871N1
- Lead Sponsor
- Yasouj University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 106
Inclusion Criteria
Thalassemic patients and Intermedia (confirmed with hemoglobin electrophoresis)
Age greater than 10 years
Patients with glucose homeostasis disorder
Patients with zinc deficiency
Exclusion Criteria
Thalassemic patients with diabetes mellitus
Glycemic control drugs
3- Liver failure
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Serum Zinc Level,Glucose Homeostasis Disorder. Timepoint: Begining of study and after 6 month. Method of measurement: - Blood serum glucose with the method,glucose oxidase and glucose peroxidase with kits of Pars Azmon Company - Insulin serum and C- peptide with Eliza method and with MonoBand Company kit - serum zinc level with atomic absorption method.
- Secondary Outcome Measures
Name Time Method 1) Insolinogenic index (evaluation of pancreatic beta cell function) 2) Insulin sensitivity & insulin resistant index 3)Impaired Fasting Glucose 4)Impaired glucose tolerance. Timepoint: Begining study and after 6 mont. Method of measurement: Fasting plasma glucose and serum glucose levels two hours after breakfast are measured with glucose oxidase and glucose peroxidase with the kits of Pars Azmon Company. Insulin and serum C-peptide are measured by the Eliza method and monobandin kits. The serum zinc is measured by atomic absorption method.